An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer

Science Translational Medicine

Volumn 2, Issue 54, 2010, Pages

  Andersen, Jesper B ^a   Factor, Valentina M ^a   Marquardt, Jens U ^a   Raggi, Chiara ^a   Lee, Yun Han ^a   Seo, Daekwan ^a   Conner, Elizabeth A ^a   Thorgeirsson, Snorri S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MYC PROTEIN; TRANSCRIPTION FACTOR E2F1; TUMOR NECROSIS FACTOR; ZEBULARINE; ANTINEOPLASTIC AGENT; CYTIDINE; DRUG DERIVATIVE; PYRIMIDIN 2 ONE BETA RIBOFURANOSIDE; PYRIMIDIN-2-ONE BETA-RIBOFURANOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DEMETHYLATION; DRUG EFFICACY; DRUG RESPONSE; EPIGENETICS; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LUNG METASTASIS; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENT CANCER; SOLID TUMOR; SURVIVAL RATE; TRANSCRIPTOMICS; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CPG ISLAND; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HUMAN GENOME; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CPG ISLANDS; CYTIDINE; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; LIVER NEOPLASMS; MICE; TRANSPLANTATION, HETEROLOGOUS;

EID: 77958610661     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001338     Document Type: Article

References (47)

1. D. M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. A. L. Cheng, Y. K. Kang, Z. Chen, C. J. Tsao, S. Qin, J. S. Kim, R. Luo, J. Feng, S. Ye, T. S. Yang, J. Xu, Y. Sun, H. Liang, J. Liu, J. Wang, W. Y. Tak, H. Pan, K. Burock, J. Zou, D. Voliotis, Z. Guan, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
3. J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J. F. Blanc, A. C. de Oliveira, A. Santoro, J. L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T. F. Greten, P. R. Galle, J. F. Seitz, I. Borbath, D. Haussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, J. Bruix, Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
4. J. M. Llovet, A. Burroughs, J. Bruix, Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003).
5. J. S. Lee, I. S. Chu, J. Heo, D. F. Calvisi, Z. Sun, T. Roskams, A. Durnez, A. J. Demetris, S. S. Thorgeirsson, Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40, 667-676 (2004).
6. J. S. Lee, J. Heo, L. Libbrecht, I. S. Chu, P. Kaposi-Novak, D. F. Calvisi, A. Mikaelyan, L. R. Roberts, A. J. Demetris, Z. Sun, F. Nevens, T. Roskams, S. S. Thorgeirsson, A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 12, 410-416 (2006).
7. J. S. Lee, S. S. Thorgeirsson, Genome-scale profiling of gene expression in hepatocellular carcinoma: Classification, survival prediction, and identification of therapeutic targets. Gastroenterology 127, S51-S55 (2004).
8. A. Villanueva, P. Newell, D. Y. Chiang, S. L. Friedman, J. M. Llovet, Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27, 55-76 (2007).
9. A. Villanueva, S. Toffanin, J. M. Llovet, Linking molecular classification of hepatocellular carcinoma and personalized medicine: Preliminary steps. Curr. Opin. Oncol. 20, 444-453 (2008).
10. A. P. Feinberg, The epigenetics of cancer etiology. Semin. Cancer Biol. 14, 427-432 (2004).
11. A. P. Feinberg, B. Tycko, The history of cancer epigenetics. Nat. Rev. Cancer 4, 143-153 (2004).
12. D. F. Calvisi, S. Ladu, A. Gorden, M. Farina, J. S. Lee, E. A. Conner, I. Schroeder, V. M. Factor, S. S. Thorgeirsson, Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J. Clin. Invest. 117, 2713-2722 (2007).
13. A. Bird, DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6-21 (2002).
14. J. P. Issa, DNA methylation as a therapeutic target in cancer. Clin. Cancer Res. 13, 1634-1637 (2007).
15. C. B. Yoo, P. A. Jones, Epigenetic therapy of cancer: Past, present and future. Nat. Rev. Drug Discov. 5, 37-50 (2006).
16. H. Dote, D. Cerna, W. E. Burgan, D. J. Carter, M. A. Cerra, M. G. Hollingshead, K. Camphausen, P. J. Tofilon, Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin. Cancer Res. 11, 4571-4579 (2005).
17. J. P. Issa, H. M. Kantarjian, Targeting DNA methylation. Clin. Cancer Res. 15, 3938-3946 (2009).
18. D. Neureiter, S. Zopf, T. Leu, O. Dietze, C. Hauser-Kronberger, E. G. Hahn, C. Herold, M. Ocker, Apoptosis, proliferation and differentiation patterns are influenced by zebularine and SAHA in pancreatic cancer models. Scand. J. Gastroenterol. 42, 103-116 (2007).
19. A. Pinto, V. Zagonel, 5-Aza-2′-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends. Leukemia 7 (Suppl. 1), 51-60 (1993).
20. G. Schwartsmann, H. Schunemann, C. N. Gorini, A. F. Filho, C. Garbino, G. Sabini, I. Muse, L. DiLeone, D. R. Mans, A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest. New Drugs 18, 83-91 (2000).
21. J. C. Cheng, C. B. Yoo, D. J. Weisenberger, J. Chuang, C. Wozniak, G. Liang, V. E. Marquez, S. Greer, T. F. Orntoft, T. Thykjaer, P. A. Jones, Preferential response of cancer cells to zebularine. Cancer Cell 6, 151-158 (2004).
22. J. C. Cheng, C. B.Matsen, F. A. Gonzales, W. Ye, S. Greer, V. E. Marquez, P. A. Jones, E. U. Selker, Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst. 95, 399-409 (2003).
23. C. B. Yoo, J. C. Cheng, P. A. Jones, Zebularine: A new drug for epigenetic therapy. Biochem. Soc. Trans. 32, 910-912 (2004).
24. J. C. Cheng, D. J. Weisenberger, F. A. Gonzales, G. Liang, G. L. Xu, Y. G. Hu, V. E. Marquez, P. A. Jones, Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell. Biol. 24, 1270-1278 (2004).
25. V. E. Marquez, R. Eritja, J. A. Kelley, D. Vanbemmel, J. K. Christman, Potent inhibition of HhaI DNA methylase by the aglycon of 2-(1H)-pyrimidinone riboside (zebularine) at the GCGC recognition domain. Ann. N. Y. Acad. Sci. 1002, 154-164 (2003).
26. D. M. van Bemmel, A. S. Brank, R. Eritja, V. E. Marquez, J. K. Christman, DNA (cytosine-C5) methyltransferase inhibition by oligodeoxyribonucleotides containing 2-(1H)-pyrimidinone (zebularine aglycon) at the enzymatic target site. Biochem. Pharmacol. 78, 633-641 (2009).
27. A. P. Feinberg, R. Ohlsson, S. Henikoff, The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7, 21-33 (2006).
28. M. Bibikova, E. Chudin, B. Wu, L. Zhou, E. W. Garcia, Y. Liu, S. Shin, T. W. Plaia, J. M. Auerbach, D. E. Arking, R. Gonzalez, J. Crook, B. Davidson, T. C. Schulz, A. Robins, A. Khanna, P. Sartipy, J. Hyllner, P. Vanguri, S. Savant-Bhonsale, A. K. Smith, A. Chakravarti, A. Maitra, M. Rao, D. L. Barker, J. F. Loring, J. B. Fan, Human embryonic stem cells have a unique epigenetic signature. Genome Res. 16, 1075-1083 (2006).
29. M. Bibikova, Z. Lin, L. Zhou, E. Chudin, E. W. Garcia, B. Wu, D. Doucet, N. J. Thomas, Y. Wang, E. Vollmer, T. Goldmann, C. Seifart, W. Jiang, D. L. Barker, M. S. Chee, J. Floros, J. B. Fan, High-throughput DNA methylation profiling using universal bead arrays. Genome Res. 16, 383-393 (2006).
30. J. B. Andersen, R. Loi, A. Perra, V. M. Factor, G. M. Ledda-Columbano, A. Columbano, S. S. Thorgeirsson, Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology 51, 1401-1409 (2010).
31. M. Gardiner-Garden, M. Frommer, CpG islands in vertebrate genomes. J. Mol. Biol. 196, 261-282 (1987).
32. D. Takai, P. A. Jones, Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. U.S.A. 99, 3740-3745 (2002).
33. J. H. Beumer, E. Joseph, M. J. Egorin, R. S. Parker, D. Z. D'Argenio, J. M. Covey, J. L. Eiseman, A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice. Clin. Cancer Res. 12, 5826-5833 (2006).
34. J. L. Holleran, R. A. Parise, E. Joseph, J. L. Eiseman, J. M. Covey, E. R. Glaze, A. V. Lyubimov, Y. F. Chen, D. Z. D'Argenio, M. J. Egorin, Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin. Cancer Res. 11, 3862-3868 (2005).
35. R. W. Klecker, R. L. Cysyk, J. M. Collins, Zebularine metabolism by aldehyde oxidase in hepatic cytosol from humans, monkeys, dogs, rats, and mice: Influence of sex and inhibitors. Bioorg. Med. Chem. 14, 62-66 (2006).
36. V. K. Mootha, C. M. Lindgren, K. F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver, E. Carlsson, M. Ridderstrale, E. Laurila, N. Houstis, M. J. Daly, N. Patterson, J. P. Mesirov, T. R. Golub, P. Tamayo, B. Spiegelman, E. S. Lander, J. N. Hirschhorn, D. Altshuler, L. C. Groop, PGC-1α- responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
37. H. B. El-Serag, K. L. Rudolph, Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576 (2007).
38. L. Bullinger, S. A. Armstrong, HELP for AML: Methylation profiling opens new avenues. Cancer Cell 17, 1-3 (2010).
39. M. E. Figueroa, S. Lugthart, Y. Li, C. Erpelinck-Verschueren, X. Deng, P. J. Christos, E. Schifano, J. Booth, W. van Putten, L. Skrabanek, F. Campagne, M. Mazumdar, J. M. Greally, P. J. Valk, B. Lowenberg, R. Delwel, A. Melnick, DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13-27 (2010).
40. G. B. West, J. H. Brown, B. J. Enquist, A general model for the origin of allometric scaling laws in biology. Science 276, 122-126 (1997).
41. J. A. Balfour, K. L. Goa, Raloxifene. Drugs Aging 12, 335-341 (1998).
42. V. L. Galinsky, Automatic registration of microarray images. II. Hexagonal grid. Bioinformatics 19, 1832-1836 (2003).
43. K. Kuhn, S. C. Baker, E. Chudin, M. H. Lieu, S. Oeser, H. Bennett, P. Rigault, D. Barker, T. K. McDaniel, M. S. Chee, A novel, high-performance random array platform for quantitative gene expression profiling. Genome Res. 14, 2347-2356 (2004).
44. J. B. Fan, J. M. Yeakley, M. Bibikova, E. Chudin, E. Wickham, J. Chen, D. Doucet, P. Rigault, B. Zhang, R. Shen, C. McBride, H. R. Li, X. D. Fu, A. Oliphant, D. L. Barker, M. S. Chee, A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res. 14, 878-885 (2004).
45. X. Cui, G. A. Churchill, Statistical tests for differential expression in cDNA microarray experiments. Genome Biol. 4, 210 (2003).
46. E. Chudin, S. Kruglyak, S. C. Baker, S. Oeser, D. Barker, T. K. McDaniel, A model of technical variation of microarray signals. J. Comput. Biol. 13, 996-1003 (2006).
47. Acknowledgments: We thank D. Menon-Andersen for advice concerning zebularine pharmacokinetics and J. W. Grisham for histopathological examination. We are grateful to S. Garfield and L. Lim for assistance with confocal microscopy, A. Holczbauer for providing mCherry-expressing lentivirus, and A. Olson for proofreading the manuscript. Funding: Supported by the Intramural Research Program of the NIH, NCI, Center for Cancer Research. Author contributions: J.B.A., V.M.F., J.U.M., and C.R. performed all experiments; S.S.T. provided funding; J.B.A., V.M.F., and S.S.T. wrote the paper; E.A.C., Y.-H.L., and D.S. provided materials and tools. Competing interests: The authors declare that they have no competing interests. Accession numbers: Microarray data were submitted to Gene Expression Omnibus and can be accessed via GSE23991.